Geneos Personalized Neoantigen-Targeting Vaccine (GNOS-PV02) to be Utilized in Innovative GT-30 Hepatocellular Carcinoma Trial Jeff Richardson. Feb 2020.
Geneos Therapeutics Announces First Patient Dosed with its DNA-based, Neoantigen-Targeting Personalized Vaccine Technology
Texas Based CMO VGXI and Geneos Therapeutics Establish Supply Agreement for Production of GT- EPIC-Based Personalized Cancer Therapeutics
Geneos Therapeutics Secures $10.5 Million in Series A Financing to Develop the Next Generation of Neoantigen-Targeting Cancer Immunotherapies